SKIN: The Journal of Cutaneous MedicineTM, Clinically Important Considerations with the Use of Oral Doxycycline
NEW YORK, NY, UNITED STATES, November 16, 2017 /EINPresswire.com/ — Doxycycline is a commonly prescribed antibiotic of the tetracycline family used to treat a variety of conditions. Dermatologists, who utilize the medication to treat skin infections and other conditions such as acne and rosacea, are among the most common prescribers of this medication.
Although the medication has been in use for many years, its unique profile of potential adverse effects necessitates that prescribers have several important considerations in mind when contemplating its use.
A new article published today in SKIN: The Journal of Cutaneous Medicine highlights the unique characteristics of doxycycline and details four practical tips to optimize therapeutic success with the drug and avoid adverse effects including the development of antibiotic resistance.
James Del Ross, DO, a dermatologist who specializes in dermatologic pharmacology, outlines important considerations health care providers should consider when prescribing doxycycline. These tips touch on ways to minimize gastrointestinal irritation and phototoxic side effects of the drug. According to Del Rosso, “Ingestion with a large glass of water and food while maintaining an upright position can prevent [stomach irritation], while prevention of [sensitivity to the sun] warrants photoprotection measures that includes use of a sunscreen that filters out the full UVA spectrum.”
SKIN: The Journal of Cutaneous MedicineTM is a peer-reviewed online medical journal that is the official journal of The National Society for Cutaneous Medicine. The mission of SKIN is to provide an enhanced and accelerated route to disseminate new dermatologic knowledge for all aspects of cutaneous disease.
For more details please visit www.jofskin.org or contact email@example.com.
Editors’ Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
James Del Rosso
email us here
Source: EIN Presswire